30 October 2019
MSIF’s international working group on access, in which MPP participated, met in July to advance the global agenda on access to treatments. One of the suggested actions from the meeting is that “the MS Community should collaborate with the MPP, sharing MS-specific expertise and data where necessary, to evaluate opportunity for access-oriented licensing for certain MS drugs (e.g. cladribine) to facilitate availability of quality assured generic medicines and price reductions through generic competition.”
Access the full meeting report
Access MSIF’s article on the meeting “The next steps for improving access to treatments around the world“
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.